Golden State Equity Partners’s AstraZeneca AZN Stock Holding History

Golden State Equity Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$379	Sell	2 -6,936	-100%	-$1.3M	﹤0.01%	353
2026 Q1	$1.37M	Buy	6,938 +2,641	+61%	+$509K	0.1%	221
2025 Q4	$790K	Buy	4,297 +349	+9%	+$61.2K	0.13%	182
2025 Q3	$606K	Buy	3,948 +428	+12%	+$64.8K	0.1%	231
2025 Q2	$492K	Buy	3,520 +292	+9%	+$40.9K	0.09%	248
2025 Q1	$474K	Buy	3,228 +323	+11%	+$46.7K	0.09%	252
2024 Q4	$381K	Buy	2,905 +534	+23%	+$74.8K	0.07%	283
2024 Q3	$369K	Buy	+2,371	New	+$383K	0.06%	307

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Golden State Equity Partners's AZN Position: Q2 2026 in Review

Golden State Equity Partners reduced its AstraZeneca (AZN) stake by 100% in Q2 2026, selling an estimated $1.3M and leaving 2 shares worth $379. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Golden State Equity Partners first reported a position in AZN in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.37M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Golden State Equity Partners held 2 shares of AstraZeneca worth $379 as of Q2 2026.
Golden State Equity Partners sold 6,936 AstraZeneca shares in Q2 2026, an estimated $1.3M.
AstraZeneca made up ﹤0.01% of Golden State Equity Partners's portfolio in Q2 2026, its #353 holding.
Golden State Equity Partners first reported a position in AstraZeneca in Q3 2024 and has held it in 8 quarters since.
Golden State Equity Partners's AstraZeneca position peaked at $1.37M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.